GHRP + GHRH Combination Protocol

GHRP peptides (such as Ipamorelin) stimulate GH release via the ghrelin receptor (GHS-R1a), while GHRH analogs (such as Sermorelin or CJC-1295) stimulate GH release via the GHRH receptor. These two pathways are complementary and produce synergistic — not merely additive — GH release when activated simultaneously. Research shows the combination can produce 3-10x greater GH output than either peptide alone.

Use the Dosing Calculation Protocol to calculate the injection volume for each peptide separately. Typical research doses in the literature: Ipamorelin 100-300 mcg, Sermorelin 100-200 mcg, CJC-1295 (no DAC) 100-200 mcg. Each peptide should be drawn into a separate syringe — do not mix peptides in the same syringe.

For maximum synergistic GH release, both peptides should be administered within the same approximate timeframe. Research protocols typically administer the GHRH analog first, followed immediately by the GHRP (within 1-2 minutes). The key principle is simultaneous receptor activation.

Following the Subcutaneous Injection Technique Protocol, administer the GHRH analog (Sermorelin, CJC-1295, or Tesamorelin) at the first injection site. Record the time of administration.

Using a fresh syringe and a different injection site, administer the GHRP (Ipamorelin) following the same subcutaneous injection technique. Record the time. The interval between the two injections should be no more than 5 minutes.

For optimal GH release, research protocols typically require a fasted state. Avoid food intake for 1-2 hours before and 30-60 minutes after administration. Fats and carbohydrates in particular can blunt the GH response by elevating insulin and free fatty acids.

Research protocols typically employ 1-3 administrations per day (e.g., morning fasted, post-workout, and before bed). Studies often run 8-12 week cycles with periodic breaks to prevent receptor desensitization. Monitor and record observations throughout the research period.